Stella Pharma Corporation (TYO:4888)
Japan
· Delayed Price · Currency is JPY 383.00
+26.00 (7.28%)
May 30, 2025, 3:30 PM JST
Stella Pharma Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2019 - 2020 |
| Cash & Equivalents | 3,206 | 2,052 | 2,710 | 3,276 | 1,251 | Upgrade
|
| Short-Term Investments | - | 300 | - | - | - | Upgrade
|
| Cash & Short-Term Investments | 3,206 | 2,352 | 2,710 | 3,276 | 1,251 | Upgrade
|
| Cash Growth | 36.31% | -13.21% | -17.28% | 161.87% | -37.67% | Upgrade
|
| Accounts Receivable | 714 | 76 | 59 | 16 | 55 | Upgrade
|
| Receivables | 714 | 76 | 59 | 16 | 55 | Upgrade
|
| Inventory | 1,230 | 1,116 | 940 | 773 | 392 | Upgrade
|
| Prepaid Expenses | 49 | 40 | 39 | 36 | 40 | Upgrade
|
| Other Current Assets | 44 | 45 | 44 | 74 | 72 | Upgrade
|
| Total Current Assets | 5,243 | 3,629 | 3,792 | 4,175 | 1,810 | Upgrade
|
| Property, Plant & Equipment | 66 | 81 | 102 | 92 | 68 | Upgrade
|
| Long-Term Investments | 57 | 57 | 371 | 382 | 89 | Upgrade
|
| Other Intangible Assets | 49 | 52 | 61 | 68 | 79 | Upgrade
|
| Other Long-Term Assets | 2 | 1 | 3 | 1 | 2 | Upgrade
|
| Total Assets | 5,417 | 3,820 | 4,329 | 4,718 | 2,048 | Upgrade
|
| Accounts Payable | 22 | 75 | 49 | 48 | 62 | Upgrade
|
| Accrued Expenses | 7 | 4 | 6 | 2 | 47 | Upgrade
|
| Current Portion of Long-Term Debt | 158 | 160 | 160 | 160 | 160 | Upgrade
|
| Current Income Taxes Payable | 197 | 212 | 202 | 92 | 45 | Upgrade
|
| Other Current Liabilities | 6 | 4 | 4 | 6 | 5 | Upgrade
|
| Total Current Liabilities | 390 | 455 | 421 | 308 | 319 | Upgrade
|
| Long-Term Debt | 608 | 773 | 933 | 1,093 | 1,253 | Upgrade
|
| Other Long-Term Liabilities | 1,153 | 163 | 176 | 187 | 200 | Upgrade
|
| Total Liabilities | 2,210 | 1,444 | 1,577 | 1,639 | 1,818 | Upgrade
|
| Common Stock | 2,859 | 2,938 | 3,300 | 3,808 | 1,999 | Upgrade
|
| Additional Paid-In Capital | 489 | 195 | 220 | 1,908 | 99 | Upgrade
|
| Retained Earnings | -140 | -763 | -778 | -2,636 | -1,869 | Upgrade
|
| Comprehensive Income & Other | -1 | 6 | 10 | -1 | 1 | Upgrade
|
| Shareholders' Equity | 3,207 | 2,376 | 2,752 | 3,079 | 230 | Upgrade
|
| Total Liabilities & Equity | 5,417 | 3,820 | 4,329 | 4,718 | 2,048 | Upgrade
|
| Total Debt | 766 | 933 | 1,093 | 1,253 | 1,413 | Upgrade
|
| Net Cash (Debt) | 2,440 | 1,419 | 1,617 | 2,023 | -162 | Upgrade
|
| Net Cash Growth | 71.95% | -12.25% | -20.07% | - | - | Upgrade
|
| Net Cash Per Share | 73.10 | 45.81 | 56.00 | 72.04 | -8.09 | Upgrade
|
| Filing Date Shares Outstanding | 34.02 | 31.22 | 29.48 | 28.65 | 20.14 | Upgrade
|
| Total Common Shares Outstanding | 34.02 | 31.22 | 29.48 | 28.65 | 20.14 | Upgrade
|
| Working Capital | 4,853 | 3,174 | 3,371 | 3,867 | 1,491 | Upgrade
|
| Book Value Per Share | 94.27 | 76.10 | 93.35 | 107.48 | 11.42 | Upgrade
|
| Tangible Book Value | 3,158 | 2,324 | 2,691 | 3,011 | 151 | Upgrade
|
| Tangible Book Value Per Share | 92.83 | 74.43 | 91.28 | 105.10 | 7.50 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.